
TY  - JOUR
TI  - Abstracts
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 122
IS  - S2
SN  - 1742-7835
UR  - https://doi.org/10.1111/bcpt.12968
DO  - doi:10.1111/bcpt.12968
SP  - 3
EP  - 67
PY  - 2018
ER  - 

TY  - JOUR
AU  - Bull, Sarah
AU  - Burnett, Karin
AU  - Vassaux, Kate
AU  - Ashdown, Lini
AU  - Brown, Terry
AU  - Rushton, Lesley
C7  - 572E
TI  - Extensive literature search and provision of summaries of studies related to the oral toxicity of perfluoroalkylated substances (PFASs), their precursors and potential replacements in experimental animals and humans. Area 1: Data on toxicokinetics (absorption, distribution, metabolism, excretion) in in vitro studies, experimental animals and humans. Area 2: Data on toxicity in experimental animals. Area 3: Data on observations in humans
JO  - EFSA Supporting Publications
JA  - EFSA Supporting Publications
VL  - 11
IS  - 4
SN  - 2397-8325
UR  - https://doi.org/10.2903/sp.efsa.2014.EN-572
DO  - doi:10.2903/sp.efsa.2014.EN-572
SP  - 572E
KW  - perfluoroalkylated substances
KW  - toxicity
KW  - in vitro
KW  - experimental animals
KW  - humans
KW  - literature search
PY  - 2014
ER  - 

AU  - Shanahan, Fergus
C7  - pp. 355-371
TI  - Ulcerative Colitis
SN  - 9781405191821
UR  - https://doi.org/10.1002/9781118321386.ch49
DO  - doi:10.1002/9781118321386.ch49
SP  - 355-371
KW  - Inflammatory bowel disease
KW  - Ulcerative colitis
KW  - Cytokine
KW  - Microbiota
KW  - Mucosa
KW  - Immunity
PY  - 2014
AB  - Summary Ulcerative colitis is a chronic relapsing inflammatory disease sharing many features with Crohn's disease but differing in being confined to the colonic mucosa, without proximal involvement or penetration to the deeper layers of the bowel, in uncomplicated cases. Ulcerative colitis has changed face over time; once considered rare, it is now a major gastroenterologic problem in the developed world with changing demographics. The first controlled clinical therapeutic trial of corticosteroids in ulcerative colitis half century ago highlighted gastroenterology as an early exponent of evidence-based medicine. More recently, the prognosis of patients with severe disease has improved with attention to detail, critical care and the advent of immunomodulatory agents. However, despite remarkable advances, ulcerative colitis remains a significant burden on healthcare resources and a cause of much individual suffering.
ER  - 

TY  - JOUR
TI  - Abstracts and Index of Authors
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
JA  - Pharmacotherapy
VL  - 32
IS  - 10
SN  - 9781405191821
UR  - https://doi.org/10.1002/j.1875-9114.2012.01219
DO  - doi:10.1002/j.1875-9114.2012.01219
SP  - e178
EP  - e320
PY  - 2012
ER  - 

TY  - JOUR
AU  - Berger, Nathan A
AU  - Besson, Valerie C
AU  - Boulares, A Hamid
AU  - Bürkle, Alexander
AU  - Chiarugi, Alberto
AU  - Clark, Robert S
AU  - Curtin, Nicola J
AU  - Cuzzocrea, Salvatore
AU  - Dawson, Ted M
AU  - Dawson, Valina L
AU  - Haskó, György
AU  - Liaudet, Lucas
AU  - Moroni, Flavio
AU  - Pacher, Pál
AU  - Radermacher, Peter
AU  - Salzman, Andrew L
AU  - Snyder, Solomon H
AU  - Soriano, Francisco Garcia
AU  - Strosznajder, Robert P
AU  - Sümegi, Balázs
AU  - Swanson, Raymond A
AU  - Szabo, Csaba
C8  - 2017-BJP-0049-RCT-G.R1
TI  - Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases
JO  - British Journal of Pharmacology
JA  - British Journal of Pharmacology
VL  - 175
IS  - 2
SN  - 9781405191821
UR  - https://doi.org/10.1111/bph.13748
DO  - doi:10.1111/bph.13748
SP  - 192
EP  - 222
PY  - 2018
AB  - The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk?benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors. Linked Articles This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc
ER  - 

TY  - JOUR
TI  - Abstracts presented at the Association of Veterinary Anaesthetists Spring meeting, Bari, Italy, 13–16 April 2011
JO  - Veterinary Anaesthesia and Analgesia
VL  - 38
IS  - 6
SN  - 9781405191821
UR  - https://doi.org/10.1111/j.1467-2995.2011.00647a.x
DO  - doi:10.1111/j.1467-2995.2011.00647a.x
SP  - 1
EP  - 35
PY  - 2011
ER  - 

TY  - JOUR
AU  - Patsalos, Andreas
AU  - Pap, Attila
AU  - Varga, Tamas
AU  - Trencsenyi, Gyorgy
AU  - Contreras, Gerardo Alvarado
AU  - Garai, Ildiko
AU  - Papp, Zoltan
AU  - Dezso, Balazs
AU  - Pintye, Eva
AU  - Nagy, Laszlo
TI  - In situ macrophage phenotypic transition is affected by altered cellular composition prior to acute sterile muscle injury
JO  - The Journal of Physiology
JA  - J Physiol
VL  - 595
IS  - 17
SN  - 9781405191821
UR  - https://doi.org/10.1113/JP274361
DO  - doi:10.1113/JP274361
SP  - 5815
EP  - 5842
KW  - bone marrow transplantation
KW  - inflammation
KW  - irradiation
KW  - macrophage polarization
KW  - muscle damage
KW  - radioprotection
KW  - regeneration
KW  - satellite cells
PY  - 2017
AB  - Key points The in situ phenotypic switch of macrophages is delayed in acute injury following irradiation. The combination of bone marrow transplantation and local muscle radiation protection allows for the identification of a myeloid cell contribution to tissue repair. PET-MRI allows monitoring of myeloid cell invasion and metabolism. Altered cellular composition prior to acute sterile injury affects the in situ phenotypic transition of invading myeloid cells to repair macrophages. There is reciprocal intercellular communication between local muscle cell compartments, such as PAX7 positive cells, and recruited macrophages during skeletal muscle regeneration. Abstract Skeletal muscle regeneration is a complex interplay between various cell types including invading macrophages. Their recruitment to damaged tissues upon acute sterile injuries is necessary for clearance of necrotic debris and for coordination of tissue regeneration. This highly dynamic process is characterized by an in situ transition of infiltrating monocytes from an inflammatory (Ly6Chigh) to a repair (Ly6Clow) macrophage phenotype. The importance of the macrophage phenotypic shift and the cross-talk of the local muscle tissue with the infiltrating macrophages during tissue regeneration upon injury are not fully understood and their study lacks adequate methodology. Here, using an acute sterile skeletal muscle injury model combined with irradiation, bone marrow transplantation and in vivo imaging, we show that preserved muscle integrity and cell composition prior to the injury is necessary for the repair macrophage phenotypic transition and subsequently for proper and complete tissue regeneration. Importantly, by using a model of in vivo ablation of PAX7 positive cells, we show that this radiosensitive skeletal muscle progenitor pool contributes to macrophage phenotypic transition following acute sterile muscle injury. In addition, local muscle tissue radioprotection by lead shielding during irradiation preserves normal macrophage transition dynamics and subsequently muscle tissue regeneration. Taken together, our data suggest the existence of a more extensive and reciprocal cross-talk between muscle tissue compartments, including satellite cells, and infiltrating myeloid cells upon tissue damage. These interactions shape the macrophage in situ phenotypic shift, which is indispensable for normal muscle tissue repair dynamics.
ER  - 

TY  - JOUR
TI  - 2017 ACVIM Forum Research Abstract Program
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 31
IS  - 4
SN  - 9781405191821
UR  - https://doi.org/10.1111/jvim.14778
DO  - doi:10.1111/jvim.14778
SP  - 1225
EP  - 1361
PY  - 2017
ER  - 

TY  - JOUR
TI  - KEYWORD INDEX
JO  - Clinical Microbiology and Infection
VL  - 12
IS  - s4
SN  - 9781405191821
UR  - https://doi.org/10.1111/j.1470-9465.2006.12_4_1453.x
DO  - doi:10.1111/j.1470-9465.2006.12_4_1453.x
PY  - 2006
ER  - 

C7  - pp. 99-120
TI  - Inflammation-Related Factors
SN  - 9781118829912
UR  - https://doi.org/10.1002/9781118829875.ch5
DO  - doi:10.1002/9781118829875.ch5
SP  - 99-120
KW  - antioxidants
KW  - cardiovascular disease
KW  - chronic inflammatory disease
KW  - dietary patterns
KW  - erythrocyte sedimentation rate
KW  - high-sensitivity-C-reactive protein
KW  - inflammation markers
KW  - Lp-PLA2
KW  - pharmacological agents
PY  - 2006
AB  - Summary This chapter reviews current knowledge of the role of inflammation in cardiovascular disease (CVD) and describes emerging markers of inflammation in CVD. It examines whether individuals identified on the basis of elevated serum high-sensitivity (hs)-C-reactive protein (CRP) benefit from clinical intervention. The chapter reviews existing guidelines relating to hs-CRP and highlights limitations in the use of hs-CRP in risk assessment. It evaluates the prognostic value of other inflammatory markers, including fibrinogen, cytokines, chemokines, adhesion molecules, serum amyloid A, albumin, leukocyte count, erythrocyte sedimentation rate, circulating immune complexes, heat-shock proteins, matrix metalloproteinases, lipoprotein-associated phospholipase A2 (Lp-PLA2), paraoxonase-1, and myeloperoxidase in CVD. The chapter reviews the influence of chronic inflammatory disease and infectious burden on CVD, and discusses relevant data regarding pharmacological agents with anti-inflammatory effects in CVD. It evaluates the influence of dietary patterns, wholegrains, dietary fat, antioxidants, phytochemicals, plant sterols, alcohol, micronutrients, physical activity, genetics, and family history on inflammatory markers associated with CVD.
ER  - 

TY  - JOUR
TI  - EAST-EUROPEAN SYMPOSIUM “CENTRAL AND PERIPHERAL SYNAPTIC TRANSMISSION” October 5–9, 2005, Varna, Bulgaria
JO  - Autonomic and Autacoid Pharmacology
VL  - 26
IS  - 1
SN  - 9781118829912
UR  - https://doi.org/10.1111/j.1474-8673.2006.00131.x
DO  - doi:10.1111/j.1474-8673.2006.00131.x
SP  - 31
EP  - 120
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts from the American Cancer Society's national conference on gynecologic cancers held April 6-8,1995, in Washington, DC
JO  - Cancer
JA  - Cancer
VL  - 75
IS  - 10
SN  - 9781118829912
UR  - https://doi.org/10.1002/1097-0142(19950515)75:10<2632::AID-CNCR2820751034>3.0.CO;2-X
DO  - doi:10.1002/1097-0142(19950515)75:10<2632::AID-CNCR2820751034>3.0.CO;2-X
SP  - 2632
EP  - 2647
PY  - 1995
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - European Journal of Pain
VL  - 11
IS  - S1
SN  - 9781118829912
UR  - https://doi.org/10.1016/j.ejpain.2007.03.150
DO  - doi:10.1016/j.ejpain.2007.03.150
SP  - S59
EP  - S207
PY  - 2007
ER  - 

TY  - JOUR
TI  - Oral presentations
JO  - Clinical Microbiology and Infection
VL  - 17
IS  - s4
SN  - 9781118829912
UR  - https://doi.org/10.1111/j.1469-0691.2011.03557.x
DO  - doi:10.1111/j.1469-0691.2011.03557.x
SP  - S1
EP  - S107
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts of the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting, Paris, France, 4-6 December 2015
JO  - Journal of Cachexia, Sarcopenia and Muscle
JA  - Journal of Cachexia, Sarcopenia and Muscle
VL  - 6
IS  - 4
SN  - 9781118829912
UR  - https://doi.org/10.1002/jcsm.12087
DO  - doi:10.1002/jcsm.12087
SP  - 398
EP  - 509
PY  - 2015
ER  - 

TY  - JOUR
TI  - Proceedings 22nd Symposium ESVN-ECVN Bologna 24th–26th September 2009
JO  - Journal of Veterinary Internal Medicine
VL  - 24
IS  - 1
SN  - 9781118829912
UR  - https://doi.org/10.1111/j.1939-1676.2009.00446.x
DO  - doi:10.1111/j.1939-1676.2009.00446.x
SP  - 235
EP  - 258
PY  - 2010
ER  - 

TY  - JOUR
TI  - ABSTRACTS – Online Panel Discussion (i-Pos)
JO  - International Journal of Rheumatic Diseases
VL  - 11
IS  - s1
SN  - 9781118829912
UR  - https://doi.org/10.1111/j.1479-8077.2008.00373.x
DO  - doi:10.1111/j.1479-8077.2008.00373.x
SP  - A84
EP  - A514
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Journal of Thrombosis and Haemostasis
JA  - Journal of Thrombosis and Haemostasis
VL  - 5
IS  - S2
SN  - 9781118829912
UR  - https://doi.org/10.1111/j.1538-7836.2007.tb00011.x
DO  - doi:10.1111/j.1538-7836.2007.tb00011.x
SP  - P-S-407
EP  - P-S-599
PY  - 2007
ER  - 

TY  - JOUR
TI  - Pharmacology and Anaesthesia
JO  - European Journal of Anaesthesiology
VL  - 18
IS  - s22
SN  - 9781118829912
UR  - https://doi.org/10.1046/j.1365-2346.2001.00001.x
DO  - doi:10.1046/j.1365-2346.2001.00001.x
SP  - 1
EP  - 42
PY  - 2001
ER  - 

TY  - JOUR
TI  - Oral Sessions
JO  - Transplant International
VL  - 24
IS  - s2
SN  - 9781118829912
UR  - https://doi.org/10.1111/j.1432-2277.2011.01346.x
DO  - doi:10.1111/j.1432-2277.2011.01346.x
SP  - 1
EP  - 95
PY  - 2011
ER  - 
